睿知中国疾病研究地图
候选清单0

徐州徐州医科大学

徐州医科大学附属医院

Affiliated Hospital of Xuzhou Medical University

在本站收录的 53 种疾病中,这家医院列在其中 17 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

徐州医科大学附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma33 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer17 篇牵头论文
  5. 骨肉瘤Osteosarcoma9 篇牵头论文
  6. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma37 篇牵头论文牵头 3 项开放试验
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  10. 再生障碍性贫血Aplastic anaemia5 篇牵头论文
  11. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  12. 血友病 AHaemophilia A0 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 重症肌无力Myasthenia gravis13 篇牵头论文牵头 1 项开放试验
  15. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  16. 白塞病Behçet disease0 篇牵头论文
  17. IgA 肾病IgA nephropathy0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025

徐州有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能放疗技术免疫治疗
论文中的科室肿瘤内科神经内科
牵头的论文5
  1. A prognostic nomogram for patients with III-IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Collagen alpha-5(IV) chain activation by nuclear factor 1/C promotes nasopharyngeal carcinoma progression.2025Human cell
  3. Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  4. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.2023Frontiers in immunology免费全文
  5. A case of nasopharyngeal carcinoma presenting as Susac syndrome.2021British journal of hospital medicine (London, England : 2005)
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. EBV CAR-T Cells for Nasopharyngeal Carcinoma状态不明NCT05654077牵头方早期I期2022-01 启动
  2. BGT007 Cell Treatment of Nasopharyngeal Carcinoma状态不明NCT05616468牵头方早期I期2022-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

徐州有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题新辅助与综合治疗放疗免疫治疗
论文中的科室放疗科
牵头的论文4
  1. Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression.2025Molecular immunology
  2. USP33 is an integrin α6 deubiquitinase and promotes esophageal squamous cell carcinoma cell migration and metastasis.2024Journal of cancer research and clinical oncology免费全文
  3. High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.2022PloS one免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  6. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  7. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  8. A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)状态不明NCT03958890研究中心III期2019-06 启动
  9. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  10. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)5
  1. Correlation of SOAT1 and TREM1 expression with clinicopathological features and prognosis in esophageal squamous cell carcinoma2025DOAJ (DOAJ: Directory of Open Access Journals)论文
  2. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncology论文
  3. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncology论文
  4. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology论文
  5. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncology论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 33 篇,占 0.2%。

牵头论文
33
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 7720232024: 101020242025: 10102025

徐州有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
    分期
    I/II期
    开始
    2022-02
    登记号
    NCT05323201

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:徐州医科大学附属医院徐州

  2. 正在招募
    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-12
    登记号
    NCT07317414

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京协和医院;另有 2 家列出的医院为研究中心北京、南京、徐州

  3. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  4. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室肿瘤内科普外/肝胆胰外科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文33
  1. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity.2026Cell
  2. PPP1CA promotes hepatocellular carcinoma progression in a YAP1-dependent way.2025Cellular signalling
  3. PDLIM2 deficiency mediated by PBXIP1 promotes the proliferation of HCC cells through reducing the polyubiquitination and degradation of TRIM27.2025European journal of medical research免费全文
  4. Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.2025Frontiers in immunology免费全文
  5. USP13 Facilitates the Proliferation of Hepatocellular Carcinoma Cells by Reducing K48/63-Linked Polyubiquitination and Degradation of PRPF6.2025Journal of cellular and molecular medicine免费全文
  6. Symptom Cluster Trajectories Among Patients With Hepatocellular Carcinoma After Partial Hepatectomy: A Longitudinal Study.2025Journal of clinical nursing
  7. A preoperative prediction model for microvascular invasion in hepatocellular carcinoma based on inflammatory biomarkers.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  8. FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma.2025Nature communications免费全文
  9. Identification of TSEN15 as a novel biomarker for diagnosis, prognosis, and immune infiltration in hepatocellular carcinoma.2025Scientific reports免费全文
  10. Impact of frailty on the long-term prognosis of the elderly with hepatocellular carcinoma treated with transarterial chemoembolization.2025Scientific reports免费全文
  11. Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy.2025World journal of gastroenterology免费全文
  12. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.2024Biochemical genetics
  13. RABIF promotes hepatocellular carcinoma progression through regulation of mitophagy and glycolysis.2024Communications biology免费全文
  14. SIAH2 suppresses c-JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  15. Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Journal of gastrointestinal and liver diseases : JGLD
  16. NUP37 accumulation mediated by TRIM28 enhances lipid synthesis to accelerate HCC progression.2024Oncogene
  17. The high expression of ADRM1 in hepatocellular carcinoma is closely related to tumor immune infiltration and is regulated by miR-891a-5p.2024Scientific reports免费全文
  18. Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma.2024Technology in cancer research & treatment免费全文
  19. Ubiquitin ligase NEDD4 promotes the proliferation of hepatocellular carcinoma cells through targeting PCDH17 protein for ubiquitination and degradation.2024The Journal of biological chemistry免费全文
  20. Nucleolin malonylation as a nuclear-cytosol signal exchange mechanism to drive cell proliferation in Hepatocarcinoma by enhancing AKT translation.2024The Journal of biological chemistry免费全文
  21. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.2024World journal of gastroenterology免费全文
  22. Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.2023BMC cancer免费全文
  23. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.2023BMC medical genomics免费全文
  24. SIAH1/CTR9 axis promotes the epithelial-mesenchymal transition of hepatocellular carcinoma.2023Carcinogenesis
  25. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.2023Frontiers in cellular and infection microbiology免费全文
  26. The prognostic value of the tertiary lymphoid structure in gastrointestinal cancers.2023Frontiers in immunology免费全文
  27. Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.2023Journal of gastrointestinal and liver diseases : JGLD
  28. Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis.2023Journal of gastrointestinal and liver diseases : JGLD
  29. Transcriptional regulator CTR9 promotes hepatocellular carcinoma progression and metastasis via increasing PEG10 transcriptional activity.2022Acta pharmacologica Sinica免费全文
  30. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2022Journal of gastrointestinal and liver diseases : JGLD
  31. Circular RNA circ_0021093 regulates miR-432/Annexin A2 pathway to promote hepatocellular carcinoma progression.2021Anti-cancer drugs
  32. ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.2021Carcinogenesis
  33. Long non‑coding RNA ST8SIA6‑AS1 promotes the migration and invasion of hypoxia‑treated hepatocellular carcinoma cells through the miR‑338/MEPCE axis.2021Oncology reports免费全文
中文论文(未计入)1
  1. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with sec2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer正在招募NCT05323201牵头方I/II期2022-02 启动
  2. β-alanine in the Treatment of Advanced Hepatocellular Carcinoma正在招募NCT07317414研究中心II期2025-12 启动
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  5. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.2%。

牵头论文
17
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 5520232024: 3320242025: 552025

徐州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  3. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  4. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  5. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能免疫与靶向药物
论文中的科室肿瘤内科消化/肝病科普外/肝胆胰外科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文17
  1. BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19-YBX1 Axis to Induce Immune Evasion in Gastric Cancer.2025Cancer immunology research免费全文
  2. Modeling the pre-metastatic niche of gastric cancer peritoneal metastasis under spatiotemporal resolution and investigating EVs-mediated immune suppression.2025Frontiers in immunology免费全文
  3. Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.2025Frontiers in immunology免费全文
  4. The association between psychological status and the development of early gastric cancer from atrophic gastritis.2025Medicine免费全文
  5. Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy.2025World journal of gastroenterology免费全文
  6. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.2024Archives of virology
  7. CA19‑9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy.2024BMC surgery免费全文
  8. The value of machine learning approaches in the diagnosis of early gastric cancer: a systematic review and meta-analysis.2024World journal of surgical oncology免费全文
  9. Effect of COP1 in Promoting the Tumorigenesis of Gastric Cancer by Down-Regulation of CDH18 via PI3K/AKT Signal Pathway.2023Analytical cellular pathology (Amsterdam)免费全文
  10. Clinicopathological and prognostic significance of elevated BTF3 expression in gastric cancer.2023Cellular and molecular biology (Noisy-le-Grand, France)
  11. TSPAN8 regulates EGFR/AKT pathway to enhance metastasis in gastric cancer.2023Molecular biology reports
  12. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer.2023Scientific reports免费全文
  13. Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis.2023World journal of gastroenterology免费全文
  14. The expression of long non-coding RNA LINC01279 in gastric adenocarcinoma and its clinical significance.2022Asian journal of surgery
  15. The adenosine-A2a receptor regulates the radioresistance of gastric cancer via PI3K-AKT-mTOR pathway.2022International journal of clinical oncology
  16. CD36: an emerging therapeutic target for cancer and its molecular mechanisms.2022Journal of cancer research and clinical oncology免费全文
  17. Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression.2021Clinical and translational medicine免费全文
中文论文(未计入)1
  1. [The value of a nomogram based on clinical data and contrast enhanced CT radiomics in the preoperative prediction of Epstein-Barr virus-associated gastric carcinoma].2022Zhonghua yi xue za zhiRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  2. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  3. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  5. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  8. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  9. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  10. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  11. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  12. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.4%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 0020232024: 1120242025: 112025

徐州有 11 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科儿科

这些论文过半是实验室或动物研究。

牵头的论文9
  1. Bimetallic nanoconjugate hijack Fe-S clusters to drive a closed-loop cuproptosis-ferroptosis strategy for osteosarcoma inhibition.2026Journal of colloid and interface science
  2. Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca2+/AMPK pathway.2025Redox report : communications in free radical research
  3. A meta-analysis of the efficacy and safety of first-line chemotherapeutic agents for osteosarcoma.2024Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  4. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.2022Bioengineered
  5. Long non-coding RNA long intergenic non-coding 00641 mediates cell progression with stimulating cisplatin-resistance in osteosarcoma cells via microRNA-320d/myeloid cell leukemia-1 axis.2022Bioengineered
  6. Circular RNA_ANKIB1 accelerates chemo-resistance of osteosarcoma via binding microRNA-26b-5p and modulating enhancer of zeste homolog 2.2022Bioengineered
  7. ADCK1 is a potential therapeutic target of osteosarcoma.2022Cell death & disease
  8. Anisotropic Truncated Octahedral Au with Pt Deposition on Arris for Localized Surface Plasmon Resonance-Enhanced Photothermal and Photodynamic Therapy of Osteosarcoma.2021ACS applied materials & interfaces
  9. Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcoma.2021Journal of cancer research and clinical oncology
早期论文(2016–2020 年)5
  1. MicroRNA-150-5p inhibits proliferation and invasion of osteosarcoma cells by down-regulating VEGFA.2020European review for medical and pharmacological sciences
  2. Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma.2018Bioscience reports
  3. Prognostic factors to survival of patients with chondroblastic osteosarcoma.2018Medicine
  4. Investigating ego modules and pathways in osteosarcoma by integrating the EgoNet algorithm and pathway analysis.2017Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  5. MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.2016PloS one

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

徐州有 8 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

徐州有 1 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. Inactivation of ICAM1 inhibits metastasis and improves the prognosis of Ewing's sarcoma.2021Journal of cancer research and clinical oncology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 37 篇,占 2.2%。

牵头论文
37
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 6620222023: 8820232024: 9920242025: 11112025

徐州有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
    分期
    I/II期
    开始
    2023-12
    登记号
    NCT06196255

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:徐州医科大学附属医院徐州

  2. 即将招募
    Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
    分期
    II期
    开始
    2025-05
    登记号
    NCT06963866

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:徐州医科大学附属医院徐州

  3. 即将招募
    Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
    分期
    不分期
    开始
    2025-07
    登记号
    NCT07034755

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:徐州医科大学附属医院徐州

  4. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  5. 正在招募
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07294625

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州

  6. 正在招募
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06083207

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安

  7. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  8. 即将招募
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07399444

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州

  9. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题CAR-T 与细胞治疗复发与耐药诊断、微小残留病与危险分层
牵头的论文37
  1. LncRNA H19-Encoded Micropeptide altH19 Promotes DNA Replication and Mitosis in Myeloma Cells by Enhancing the Phosphorylation of CDK2 at Threonine 160.2026Cell proliferation免费全文
  2. Advances in NK cell therapy for multiple myeloma.2025Best practice & research. Clinical haematology
  3. Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse.2025Best practice & research. Clinical haematology
  4. ALKBH5 reverses romidepsin-mediated anti-multiple myeloma activity via regulation of m6A modification of FOXM1.2025Biochemical pharmacology
  5. Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.2025Blood免费全文
  6. Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity.2025Cellular signalling
  7. Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma.2025Cytotherapy
  8. The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.2025Frontiers in immunology免费全文
  9. Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.2025Frontiers in immunology免费全文
  10. Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.2025International urology and nephrology
  11. Single-cell transcriptomics identifies PDIA4 as a marker of progression and therapeutic vulnerability in multiple myeloma.2025Journal of translational medicine免费全文
  12. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.2025The Lancet. Haematology
  13. Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.2024American journal of hematology
  14. Halting multiple myeloma with MALT1 inhibition: suppressing BCMA-induced NF-κB and inducing immunogenic cell death.2024Blood advances免费全文
  15. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.2024Chemical research in toxicology
  16. Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.2024Clinical and experimental medicine免费全文
  17. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.2024Cytotherapy
  18. Targeting GPRC5D for multiple myeloma therapy.2024Journal of hematology & oncology免费全文
  19. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.2024Molecular and cellular biochemistry
  20. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.2024Nature communications免费全文
  21. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.2024The Lancet. Haematology
  22. Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.2023Clinical and experimental medicine
  23. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.2023Cytotherapy
  24. Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-κB signaling.2023Experimental cell research
  25. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.2023Experimental cell research
  26. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.2023Frontiers in immunology免费全文
  27. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical Oncology免费全文
  28. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.2023Journal of hematology & oncology免费全文
  29. Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.2023Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  30. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.2022Cell communication and signaling : CCS免费全文
  31. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.2022Frontiers in immunology免费全文
  32. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy.2022Frontiers in immunology免费全文
  33. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.2022Frontiers in immunology免费全文
  34. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.2022Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  35. Absolute Lymphocyte Count Prior to Lymphodepletion Impacts Outcomes in Multiple Myeloma Patients Treated with Chimeric Antigen Receptor T Cells.2022Transplantation and cellular therapy
  36. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.2021Technology in cancer research & treatment免费全文
  37. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.2021Transplantation and cellular therapy
中文论文(未计入)11
  1. [Expression of GPRC5D in newly diagnosed patients with multiple myeloma detected by flow cytometry and its prognostic value].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Fever Characteristics and Biomarker Changes of CRS in Patients with Relapsed/Refractory Multiple Myeloma after CAR-T Cell Therapy].2024Zhongguo shi yan xue ye xue za zhi
  3. [Research Advances of Exosomes in Pathogenesis of Multiple Myeloma --Review].2024Zhongguo shi yan xue ye xue za zhi
  4. [The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy].2024Zhonghua yi xue za zhi
  5. [Effect of Hemoglobin on Efficacy of CAR-T Therapy in Patients with Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  6. [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].2023Zhongguo shi yan xue ye xue za zhi
  7. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  8. [Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  9. [Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].2021Zhongguo shi yan xue ye xue za zhi
  10. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  11. [Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma即将招募NCT07034755牵头方不分期2025-07 启动
  2. Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT即将招募NCT06963866牵头方(推断)II期2025-05 启动
  3. Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)正在招募NCT06196255牵头方(推断)I/II期2023-12 启动
  4. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  5. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)即将招募NCT07399444研究中心早期I期2026-01 启动
  6. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  7. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07294625研究中心早期I期2025-12 启动
  8. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma正在招募NCT06083207研究中心I/II期2024-07 启动
  9. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  10. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  11. A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma状态不明NCT05271682研究中心I期2021-12 启动
  12. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  13. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

徐州有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  2. 正在招募
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06580301

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心南昌、广州、徐州、杭州、贵阳、长春

  3. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    分期
    I期
    开始
    2024-09
    登记号
    NCT06927466

    年龄 3 岁 至 25 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、南昌、徐州、武汉、苏州

  4. 正在招募
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05667506

    年龄 3 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆

  5. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题CAR-T 与细胞治疗儿童副作用(细胞因子释放综合征、神经毒性)
牵头的论文2
  1. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.2024Cancer
  2. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.2024Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies状态不明NCT05739227牵头方(推断)早期I期2023-03 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.正在招募NCT06927466研究中心I期2024-09 启动
  3. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia正在招募NCT06450067研究中心2024-06 启动
  4. Study of YK012 in B-cell Acute Lymphoblastic Leukemia正在招募NCT06580301研究中心I/II期2024-09 启动
  5. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)正在招募NCT05667506研究中心I/II期2023-02 启动
  6. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)正在招募NCT05579132研究中心I/II期2022-11 启动
  7. Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors状态不明NCT04814004研究中心I期2021-03 启动
  8. The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)状态不明NCT04166838研究中心早期I期2019-11 启动
  9. CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia状态不明NCT04154709研究中心I期2019-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

徐州有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07499284

    年龄 14 岁 至 未注明(登记的条件)

    牵头:苏州大学附属第一医院;另有 2 家列出的医院为研究中心徐州、杭州、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫抑制治疗儿童干细胞移植

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

徐州有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题诊断与预后EB病毒与感染诱因儿童

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

徐州有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

徐州有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 13 篇,占 2.6%。

牵头论文
13
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 3320232024: 4420242025: 332025

徐州有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
    分期
    不分期
    开始
    2026-03
    登记号
    NCT07413835

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:徐州医科大学附属医院徐州

  2. 正在招募
    Myasthenia Gravis Registry in China
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06241521

    年龄未注明(登记的条件)

    牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断生物制剂与补体抑制剂孕期、儿童与老人
论文中的科室神经内科
牵头的论文13
  1. Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.2026Annals of clinical and translational neurology免费全文
  2. A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.2025Frontiers in immunology免费全文
  3. Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.2025Frontiers in immunology免费全文
  4. Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.2025Journal of neuroinflammation免费全文
  5. Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse.2024Cytokine
  6. Increased serum interleukin-41 correlates with disease severity in myasthenia gravis.2024International immunopharmacology
  7. Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.2024Journal of neurology
  8. Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.2024Journal of neurology
  9. The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis.2023Annals of clinical and translational neurology免费全文
  10. Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis.2023Journal of neurochemistry
  11. Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  12. Increased Expression of CD95 in CD4+ Effector Memory T Cells Promotes Th17 Response in Patients with Myasthenia Gravis.2022Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  13. IL-21 enhances STAT3/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis.2021Immunologic research
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)正在招募NCT07413835牵头方不分期2026-03 启动
  2. Myasthenia Gravis Registry in China正在招募NCT06241521研究中心2024-02 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 1120242025: 002025

徐州有 3 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文4
  1. CSF3 aggravates acute exacerbation of pulmonary fibrosis by disrupting alveolar epithelial barrier integrity.2024International immunopharmacology
  2. Fatty acid metabolism-related genes in bronchoalveolar lavage fluid unveil prognostic and immune infiltration in idiopathic pulmonary fibrosis.2022Frontiers in endocrinology
  3. PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.2022Respiratory research
  4. Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing.2021Angiogenesis
中文论文(未计入)1
  1. [Interstitial lung disease revisited].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis正在招募NCT07121413研究中心II期2025-11 启动
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  7. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  8. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

徐州有 1 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

徐州有 2 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy进行中,不再招募NCT07098897牵头方III期2024-08 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

徐州医科大学附属医院

Affiliated Hospital of Xuzhou Medical University

徐州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Affiliated Hospital of Xuzhou Medical College; Second Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical university; Huai'an Affiliated Hospital of Xuzhou Medical University; Shuyang Affiliated Hospital of Xuzhou Medical University

提出更正下载数据